Table Info

Table 1.

Comparisons between patients and controls

Variable	Cases (%)	Controls (%)	P
C-reactive protein (mg/L)	16 ± 8	4 ± 4	< 0.001
sMg (mg/dL)	1.99 ± 0.28	2.07 ± 0.23	< 0.001
HypoMg (< 1.70 mg/dL)	36/294 (12.2)	19/294 (6.5)	0.016
Ferritin (mg/dL)	257 ± 241	206 ± 173	0.004
Any HFE mutation	156/281 (55.5)	103/281 (35.6)	< 0.001
Any C282Y mutation	35/281 (12.5)	12/281(4.3)	0.001
Any H63D mutation	122/284 (42.9)	87/281 (30.9)	0.007
Any S65C mutation	6/284 (2.1)	9/281 (3.2)	0.658

The data is represented as means ± standard deviation for continuous variables, and number/total (percentage for discrete variables)

Declarations

Author contributions

JASdB and FPR contributed eaqually to: Conceptualization, Data curation, Writing—review & editing. Nuria PH, Nerea PH, CVP, and MdCMC: Conceptualization, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was included within a prospective inception gout cohort study approved by Cruces University Hospital Ethics and Clinical Investigation Committee (CEIC Cruces CEIC07/15), and it complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Data can be obtained on request by contacting Fernando Perez-Ruiz (fernando.perezruiz@osakidetza.eus).

Funding

FPR was funded by a grant from Asociación de Reumatólogos de Cruces [01/2008]. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Sanmartí R, Pañella D, Brancós MA, Canela J, Collado A, Brugués J. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis. 1993;52:418–22. [DOI] [PubMed] [PMC]

Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563–70. [DOI] [PubMed]

Balderrama CK, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium pyrophosphate deposition disease and associated medical comorbidities: a national cross-sectional study of US veterans. Arthritis Care Res (Hoboken). 2017;69:1400–6. [DOI] [PubMed] [PMC]

Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M, et al. The association between ANKH promoter polymorphism and chondrocalcinosis is independent of age and osteoarthritis: results of a case–control study. Arthritis Res Ther. 2014;16:R25. [DOI] [PubMed] [PMC]

Timms AE, Sathananthan R, Bradbury L, Athanasou NA, Wordsworth BP, Brown MA. Genetic testing for haemochromatosis in patients with chondrocalcinosis. Ann Rheum Dis. 2002;61:745–7. [DOI] [PubMed] [PMC]

Ross JM, Kowalchuk RM, Shaulinsky J, Ross L, Ryan D, Phatak PD. Association of heterozygous hemochromatosis C282Y gene mutation with hand osteoarthritis. J Rheumatol. 2003;30:121–5. [PubMed]

Alizadeh BZ, Njajou OT, Hazes JM, Hofman A, Slagboom PE, Pols HA, van Duijn CM. The H63D variant in the HFE gene predisposes to arthralgia, chondrocalcinosis and osteoarthritis. Ann Rheum Dis. 2007;66:1436–42. [DOI] [PubMed] [PMC]

Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. Risk factors for pseudogout in the general population. Rheumatology (Oxford). 2012;51:2070–4. [DOI] [PubMed] [PMC]

Yang Q, Jian J, Abramson SB, Huang X. Inhibitory effects of iron on bone morphogenetic protein 2‒induced osteoblastogenesis. J Bone Miner Res. 2011;26:1188–96. [DOI] [PubMed]

10.

Uribe S, Rangel P, Pardo JP, Pereira-Da-Silva L. Interactions of calcium and magnesium with the mitochondrial inorganic pyrophosphatase from Saccharomyces cerevisiae. Eur J Biochem. 1993;217:657–60. [DOI] [PubMed]

11.

Kieboom BCT, Zietse R, Ikram MA, Hoorn EJ, Stricker BH. Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population. Pharmacoepidemiol Drug Saf. 2018;27:1166–73. [DOI] [PubMed]

12.

Mitton-Fitzgerald E, Gohr CM, Williams CM, Rosenthal AK. Identification of common pathogenic pathways involved in hemochromatosis arthritis and calcium pyrophosphate deposition disease: a review. Curr Rheumatol Rep. 2022;24:40–5. [DOI] [PubMed]

13.

Barton JC, Edwards CQ, Acton RT. HFE gene: structure, function, mutations, and associated iron abnormalities. Gene. 2015;574:179–92. [DOI] [PubMed] [PMC]

14.

de Juan D, Reta A, Castiella A, Pozueta J, Prada A, Cuadrado E. HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum Genet. 2001;9:961–4. [DOI] [PubMed]

15.

Altes A, Ruiz A, Barceló MJ, Remacha AF, Puig T, Maya AJ, et al. Prevalence of the C282Y, H63D, and S65C mutations of the HFE gene in 1,146 newborns from a region of northern Spain. Genet Test. 2004;8:407–10. [DOI] [PubMed]

16.

Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41. [DOI] [PubMed]